CY1111911T1 - Ενωσεις πυριδο (2,3-d) πυριμιδινονης και χρηση αυτων ως αναστολεων ρι3 - Google Patents
Ενωσεις πυριδο (2,3-d) πυριμιδινονης και χρηση αυτων ως αναστολεων ρι3Info
- Publication number
- CY1111911T1 CY1111911T1 CY20111100714T CY111100714T CY1111911T1 CY 1111911 T1 CY1111911 T1 CY 1111911T1 CY 20111100714 T CY20111100714 T CY 20111100714T CY 111100714 T CY111100714 T CY 111100714T CY 1111911 T1 CY1111911 T1 CY 1111911T1
- Authority
- CY
- Cyprus
- Prior art keywords
- inhibitors
- pyrimidine
- pyrimidinone compounds
- compounds
- pyrimidinone
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 title 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 abstract 2
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 abstract 2
- FQIOVOFFAYUEJN-UHFFFAOYSA-N 4-methyl-3h-pyrido[3,2-d]pyrimidin-2-one Chemical class C1=CN=C2C(C)=NC(=O)NC2=C1 FQIOVOFFAYUEJN-UHFFFAOYSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84506506P | 2006-09-15 | 2006-09-15 | |
| US94785207P | 2007-07-03 | 2007-07-03 | |
| US95262807P | 2007-07-30 | 2007-07-30 | |
| EP07804890.7A EP2074122B9 (en) | 2006-09-15 | 2007-09-03 | Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1111911T1 true CY1111911T1 (el) | 2015-11-04 |
Family
ID=38859750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20111100714T CY1111911T1 (el) | 2006-09-15 | 2011-07-20 | Ενωσεις πυριδο (2,3-d) πυριμιδινονης και χρηση αυτων ως αναστολεων ρι3 |
Country Status (41)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE514695T1 (de) | 2006-09-15 | 2011-07-15 | Pfizer Prod Inc | Pyrido(2,3-d)pyrimidinonverbindungen und ihre verwendung als pi3-inhibitoren |
| CA2683641C (en) * | 2007-04-10 | 2016-08-16 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha |
| BRPI0810175A2 (pt) * | 2007-04-11 | 2014-12-30 | Exelixis Inc | Inibidores pirididopirinidinona de p13k alfa |
| BRPI0915901A2 (pt) * | 2008-07-11 | 2015-10-27 | Novartis Ag | combinação de (a) um inibidor de fosfoinositídeo 3-quinase e (b) um modulador da via ras/raf/mek |
| CA2734486A1 (en) | 2008-08-20 | 2010-02-25 | Southern Research Institute | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| EP2331511A1 (en) | 2008-08-20 | 2011-06-15 | Schering Corporation | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| CA2734488A1 (en) | 2008-08-20 | 2010-02-25 | Southern Research Institute | Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| ES2439009T3 (es) * | 2008-08-20 | 2014-01-21 | Merck Sharp & Dohme Corp. | Derivados de piridina y pirimidina sustituidos con etenilo y su uso en el tratamiento de infecciones virales |
| PA8843901A1 (es) * | 2008-09-30 | 2010-05-26 | INHIBIDORES DE PIRIMIDINONA DE PI3K( ALFA) Y m TOR | |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| DK2651951T3 (en) | 2010-12-16 | 2014-12-08 | Hoffmann La Roche | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND PROCEDURES FOR USE THEREOF |
| US8664230B2 (en) * | 2011-03-17 | 2014-03-04 | The Asan Foundation | Pyridopyrimidine derivatives and use thereof |
| TW201306842A (zh) * | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法 |
| US9675595B2 (en) | 2011-08-31 | 2017-06-13 | Novartis Ag | Synergistic combinations of PI3K- and MEK-inhibitors |
| CN104829609B (zh) * | 2014-02-11 | 2016-08-03 | 北大方正集团有限公司 | 取代的吡啶并嘧啶化合物及其制备方法和应用 |
| CA2954189A1 (en) | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof |
| CN105330699B (zh) * | 2014-08-13 | 2018-12-04 | 山东汇睿迪生物技术有限公司 | 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用 |
| EP3549583A1 (en) | 2014-10-10 | 2019-10-09 | Pfizer Inc | Synergistic auristatin combinations |
| HRP20192065T1 (hr) | 2015-06-04 | 2020-02-21 | Pfizer Inc. | Čvrsti oblici doziranja palbocikliba |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| JP2019519593A (ja) | 2016-07-06 | 2019-07-11 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｃｈｉｇａｎ | ＭＥＫ／ＰＩ３Ｋ及びｍＴＯＲ／ＭＥＫ／ＰＩ３Ｋ生物学的経路の多官能性阻害剤、並びに同多官能性阻害剤を用いた治療方法 |
| CN109803968A (zh) | 2016-08-15 | 2019-05-24 | 辉瑞公司 | 吡啶并嘧啶酮cdk2/4/6抑制剂 |
| JP2020503289A (ja) * | 2016-12-14 | 2020-01-30 | ターベダ セラピューティクス インコーポレイテッドＴａｒｖｅｄａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Ｈｓｐ９０標的化コンジュゲート及びその製剤 |
| US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
| CN117843659A (zh) | 2018-06-15 | 2024-04-09 | 詹森药业有限公司 | 雷帕霉素类似物和其用途 |
| AU2019413683B2 (en) * | 2018-12-28 | 2025-05-22 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| US20220220103A1 (en) * | 2018-12-28 | 2022-07-14 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| US11583538B2 (en) | 2019-04-08 | 2023-02-21 | Venenum Biodesign, LLC | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors |
| KR20220128345A (ko) | 2019-12-05 | 2022-09-20 | 아나쿠리아 테라퓨틱스, 인코포레이티드 | 라파마이신 유사체 및 이의 용도 |
| CN114901664B (zh) * | 2020-01-10 | 2024-07-02 | 南京再明医药有限公司 | 吡啶酮化合物及应用 |
| WO2022075974A1 (en) * | 2020-10-06 | 2022-04-14 | Venenum Biodesign, LLC | Cyclic trex1 inhibitors |
| US11912668B2 (en) | 2020-11-18 | 2024-02-27 | Deciphera Pharmaceuticals, Llc | GCN2 and perk kinase inhibitors and methods of use thereof |
| JP2024542205A (ja) * | 2021-11-18 | 2024-11-13 | オンコノヴァ セラピューティクス， インコーポレイテッド | がんを処置するための方法および組成物 |
| WO2024254511A2 (en) | 2023-06-08 | 2024-12-12 | Nimbus Wadjet, Inc. | Wrn inhibitors |
| WO2025137599A1 (en) * | 2023-12-21 | 2025-06-26 | Nimbus Wadjet, Inc. | Wrn inhibitors |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5264437A (en) * | 1992-03-20 | 1993-11-23 | Syntex (U.S.A.) Inc. | Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones |
| MD1861G2 (ro) | 1994-11-14 | 2002-09-30 | Уорнер-Ламберт Кампэни | Derivaţi ai 6-arilpirido[2,3-d]pirimidinelor şi naftiridinelor, compoziţie farmaceutică pe baza lor, metode de tratament şi de inhibare a proliferării şi migraţiei celulei receptorului tirozinkinazei |
| CN1177960A (zh) * | 1995-03-10 | 1998-04-01 | 圣诺菲药品有限公司 | 6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法 |
| IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| US5925761A (en) | 1997-02-04 | 1999-07-20 | Sepracor Inc. | Synthesis of terfenadine and derivatives |
| US6498163B1 (en) * | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| WO1998033798A2 (en) | 1997-02-05 | 1998-08-06 | Warner Lambert Company | Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation |
| GB9904932D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy |
| AU1808601A (en) | 2000-01-27 | 2001-08-07 | Warner-Lambert Company | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease |
| DZ3308A1 (fr) | 2000-03-06 | 2001-09-27 | Warner Lambert Co | Inhibiteurs de tyrosine kinase a base de 5-alkylpyrido [2,3-d] pyrimidines |
| CN1186324C (zh) | 2000-04-27 | 2005-01-26 | 山之内制药株式会社 | 稠合杂芳基衍生物 |
| MXPA03007623A (es) | 2001-02-26 | 2003-12-04 | Tanabe Seiyaku Co | Derivado de piridopirimidina o naftiridina. |
| US7019002B2 (en) * | 2001-12-11 | 2006-03-28 | Pharmacia & Upjohn, S.P.A. | Pyridopyrimidinones derivatives as telomerase inhibitors |
| HRP20040660B1 (hr) | 2002-01-22 | 2012-10-31 | Warner-Lambert Company Llc | 2-(PIRIDIN-2-ILAMINO)-PIRIDO[2,3-d]PIRIMIDIN-7-ONI |
| JP2003321472A (ja) | 2002-02-26 | 2003-11-11 | Takeda Chem Ind Ltd | Ｇｒｋ阻害剤 |
| EP1499320B1 (en) | 2002-04-19 | 2007-08-22 | Smithkline Beecham Corporation | Novel compounds |
| US20040063658A1 (en) | 2002-05-06 | 2004-04-01 | Roberts Christopher Don | Nucleoside derivatives for treating hepatitis C virus infection |
| JP2004083587A (ja) | 2002-08-06 | 2004-03-18 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| JP2004203751A (ja) | 2002-12-24 | 2004-07-22 | Pfizer Inc | 置換６，６−ヘテロ二環式誘導体 |
| WO2004063195A1 (en) | 2003-01-03 | 2004-07-29 | Sloan-Kettering Institute For Cancer Research | Pyridopyrimidine kinase inhibitors |
| WO2004089930A1 (en) | 2003-04-02 | 2004-10-21 | Imclone Systems Incorporated | 4-fluoroquinolone derivatives and their use as kinase inhibitors |
| US20070053831A1 (en) | 2003-05-20 | 2007-03-08 | Barrio Jorge R | Methods for binding agents to b-amyloid plaques |
| KR100816945B1 (ko) | 2003-07-11 | 2008-03-25 | 워너-램버트 캄파니 엘엘씨 | 선택적인 사이클린 의존성 키나제 4 억제제로서의이세싸이오네이트 염 |
| AU2004259755A1 (en) | 2003-07-22 | 2005-02-03 | Janssen Pharmaceutica, N.V. | Quinolinone derivatives as inhibitors of c-fms kinase |
| US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| DK1713806T3 (da) | 2004-02-14 | 2013-08-05 | Irm Llc | Forbindelser og sammensætninger som proteinkinaseinhibitorer |
| CA2555724A1 (en) * | 2004-02-18 | 2005-09-09 | Warner-Lambert Company Llc | 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
| JP2007530654A (ja) | 2004-03-30 | 2007-11-01 | ファイザー・プロダクツ・インク | シグナル伝達阻害剤の組合せ |
| WO2005105097A2 (en) | 2004-04-28 | 2005-11-10 | Gpc Biotech Ag | Pyridopyrimidines for treating inflammatory and other diseases |
| US20080255162A1 (en) * | 2004-05-04 | 2008-10-16 | Warner-Lambert Company Llc | Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents |
| CA2569277A1 (en) | 2004-06-04 | 2005-12-15 | Pfizer Products Inc. | Method for treating abnormal cell growth |
| WO2006021547A1 (de) | 2004-08-26 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Pteridinone als plk (polo like kinase) inhibitoren |
| WO2006050501A2 (en) | 2004-11-03 | 2006-05-11 | University Of Kansas | Novobiocin analogues as anticancer agents |
| WO2006065703A1 (en) | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| US20060142312A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
| CA2624965A1 (en) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of pi3k.alpha. |
| KR20140105621A (ko) * | 2005-10-07 | 2014-09-01 | 엑셀리시스, 인코포레이티드 | ＰＩ３Ｋα의 피리도피리미디논 억제제 |
| EP1872922A1 (en) * | 2006-06-27 | 2008-01-02 | Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO | Method and apparatus for manufacturing a polymeric article |
| ATE539752T1 (de) | 2006-08-16 | 2012-01-15 | Exelixis Inc | Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung |
| ATE514695T1 (de) * | 2006-09-15 | 2011-07-15 | Pfizer Prod Inc | Pyrido(2,3-d)pyrimidinonverbindungen und ihre verwendung als pi3-inhibitoren |
| AU2008224941C1 (en) * | 2007-03-14 | 2013-06-27 | Exelixis Patent Company Llc | Inhibitors of the hedgehog pathway |
| BRPI0810175A2 (pt) * | 2007-04-11 | 2014-12-30 | Exelixis Inc | Inibidores pirididopirinidinona de p13k alfa |
| PA8843901A1 (es) * | 2008-09-30 | 2010-05-26 | INHIBIDORES DE PIRIMIDINONA DE PI3K( ALFA) Y m TOR | |
| JP2013525308A (ja) * | 2010-04-16 | 2013-06-20 | キュリス，インコーポレイテッド | Ｋ−ｒａｓ変異を有する癌の治療 |
-
2007
- 2007-09-03 AT AT07804890T patent/ATE514695T1/de active
- 2007-09-03 EP EP07804890.7A patent/EP2074122B9/en active Active
- 2007-09-03 PT PT07804890T patent/PT2074122E/pt unknown
- 2007-09-03 RS RS20110379A patent/RS51927B/sr unknown
- 2007-09-03 HR HRP20110621TT patent/HRP20110621T2/hr unknown
- 2007-09-03 ES ES07804890T patent/ES2366489T3/es active Active
- 2007-09-03 CN CN2007800342100A patent/CN101573358B/zh not_active Expired - Fee Related
- 2007-09-03 AU AU2007297212A patent/AU2007297212B8/en not_active Ceased
- 2007-09-03 SI SI200730715T patent/SI2074122T1/sl unknown
- 2007-09-03 KR KR1020097005342A patent/KR101099926B1/ko not_active Expired - Fee Related
- 2007-09-03 CA CA2663401A patent/CA2663401C/en not_active Expired - Fee Related
- 2007-09-03 NZ NZ575167A patent/NZ575167A/en not_active IP Right Cessation
- 2007-09-03 MX MX2009002927A patent/MX2009002927A/es active IP Right Grant
- 2007-09-03 RS RSP-2009/0104A patent/RS20090104A/sr unknown
- 2007-09-03 JP JP2009527908A patent/JP4718637B2/ja active Active
- 2007-09-03 BR BRPI0716749A patent/BRPI0716749B8/pt not_active IP Right Cessation
- 2007-09-03 GE GEAP200711157A patent/GEP20115306B/en unknown
- 2007-09-03 MY MYPI20091013A patent/MY146420A/en unknown
- 2007-09-03 ME MEP-80/09A patent/MEP8009A/xx unknown
- 2007-09-03 WO PCT/IB2007/002578 patent/WO2008032162A1/en not_active Ceased
- 2007-09-03 EA EA200970207A patent/EA016388B1/ru not_active IP Right Cessation
- 2007-09-03 PL PL07804890T patent/PL2074122T3/pl unknown
- 2007-09-03 DK DK07804890.7T patent/DK2074122T5/da active
- 2007-09-03 AP AP2009004790A patent/AP2710A/xx active
- 2007-09-12 UY UY30588A patent/UY30588A1/es not_active Application Discontinuation
- 2007-09-13 US US11/854,999 patent/US7696213B2/en not_active Expired - Fee Related
- 2007-09-13 GT GT200700077A patent/GT200700077A/es unknown
- 2007-09-13 PE PE2007001238A patent/PE20080670A1/es not_active Application Discontinuation
- 2007-09-13 AR ARP070104059A patent/AR062785A1/es not_active Application Discontinuation
- 2007-09-14 CL CL200702682A patent/CL2007002682A1/es unknown
- 2007-09-14 TW TW096134605A patent/TWI334353B/zh not_active IP Right Cessation
- 2007-09-17 HN HN2007000267A patent/HN2007000267A/es unknown
-
2009
- 2009-02-25 IL IL197243A patent/IL197243A/en active IP Right Grant
- 2009-03-02 ZA ZA200901477A patent/ZA200901477B/xx unknown
- 2009-03-11 DO DO2009000039A patent/DOP2009000039A/es unknown
- 2009-03-13 CR CR10662A patent/CR10662A/es unknown
- 2009-03-13 NI NI200900032A patent/NI200900032A/es unknown
- 2009-03-13 TN TN2009000085A patent/TN2009000085A1/fr unknown
- 2009-03-13 MA MA31707A patent/MA30709B1/fr unknown
- 2009-03-13 CU CU20090040A patent/CU23783B7/es not_active IP Right Cessation
- 2009-03-18 NO NO20091141A patent/NO342357B1/no not_active IP Right Cessation
-
2010
- 2010-02-09 US US12/702,937 patent/US8273755B2/en not_active Expired - Fee Related
-
2011
- 2011-07-20 CY CY20111100714T patent/CY1111911T1/el unknown
-
2012
- 2012-08-16 US US13/587,825 patent/US8633204B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111911T1 (el) | Ενωσεις πυριδο (2,3-d) πυριμιδινονης και χρηση αυτων ως αναστολεων ρι3 | |
| ATE542813T1 (de) | 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren | |
| EA201000113A1 (ru) | Пиразольные соединения | |
| NI201000059A (es) | Inhibidores de la cinasa c-fms. | |
| ATE346070T1 (de) | Purinderivate als kinaseinhibitoren | |
| CR10963A (es) | Compuestos de 2-amino pirimidina | |
| UY29927A1 (es) | Derivados sustituidos de la 5-fenil-2-tioxo-imidazolin-4-ona y de la 5-fenil-2-amino-imidazolidin-4-ona y sus sales, composiciones y aplicaciones | |
| UY30274A1 (es) | Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones | |
| CY1112102T1 (el) | Υποκατεστημενες πυριμιδοδιαζεπινες χρησιμες ως αναστολεις plk1 | |
| CY1109656T1 (el) | Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης | |
| ATE552255T1 (de) | 4-aminoindazole | |
| ATE429427T1 (de) | Pyrimidinderivate als orexin-rezeptorantagonisten | |
| SMP201100019B (it) | Composti organici | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| NO20070122L (no) | Quinazolinonderivater anvendelige som vanilloidantagonister | |
| EA200601391A1 (ru) | Производные хинолина для применения в качестве микобактериальных ингибиторов | |
| CY1115729T1 (el) | Τρικυκλικη ενωση και φαρμακευτικη χρηση αυτης | |
| ATE513818T1 (de) | Chinazolinonderivate als tubulinpolymerisationshemmer | |
| UY32042A (es) | Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90 | |
| EA200801145A1 (ru) | Спироциклические производные хиназолина в качестве ингибиторов pde7 | |
| EA200801366A1 (ru) | Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина | |
| EA200800070A1 (ru) | Производные 2-(1h-индолилсульфанил)ариламина | |
| DK1819704T3 (da) | Pyrrolopyridin-2-carboxylsyre-amid-derivat anvendelig som inhibitor af glycogenphosphorylase | |
| CY1114196T1 (el) | Αρυλο σουλφοναμιδο αμινοενωσεις και χρηση αυτων ως συνδετων 5-ητ6 | |
| UA95113C2 (en) | Pyrido (2,3-d) pyrimidin0ne compounds and their use as pi3 inhibitors |